Exploiting Lactoferricin (17-30) as a Potential Antimicrobial and Antibiofilm Candidate Against Multi-Drug-Resistant Enteroaggregative Escherichia coli.

摘要: The study evaluated the in vitro antimicrobial and antibiofilm efficacy of an peptide (AMP), lactoferricin (17-30) [Lfcin (17-30)], against biofilm-forming multi-drug-resistant (MDR) strains enteroaggregative Escherichia coli (EAEC), subsequently, vivo was assessed a Galleria mellonella larval model. Initially, minimum inhibitory concentration (MIC; 32 μM), bactericidal (MBC; biofilm eradication (MBEC; μM) Lfcin were determined MDR-EAEC field isolates (n = 3). tested stable high-end temperatures (70 90°C), physiological cationic salts (150 mM NaCl 2 MgCl2), proteases (proteinase-K lysozyme). Further, at lower MIC, proved to be safe for sheep RBCs, secondary cell lines (HEp-2 RAW 264.7), beneficial gut lactobacilli. In time-kill assay, inhibited 3 h post-incubation, antibacterial effect due membrane permeation inner outer membranes MDR-EAEC. Furthermore, experiments, G. larvae treated with exhibited increased survival rate, counts (P < 0.001), mild moderate histopathological changes, enhanced immunomodulatory cells when compared infection control. Besides, effective agent, as it eradicated preformed formed by significant 0.05) manner both microtiter plate assay live/dead bacterial quantification-based confocal microscopy. We recommend further investigation appropriate animal model before its application target host strains.